Evaluación angiográfica de la reestenosis intrastent en pacientes tratados con endoprótesis bioabsorbible, stent y balón medicados

BACKGROUND: Coronary stent restenosis is a neointimal hyperplasia, which leads to the obstruction of the previously treated lesion. Its incidence is around 10%. The treatment is a new intervention with balloon angioplasty and implantation of a new stent to reestablish blood flow. OBJECTIVE: To determine if there is a difference between the different treatment strategies against intrastent restenosis such as the bioabsorbable endoprosthesis, drug-eluting stent and drug-eluting balloon, evaluated by angiography after 12 months of being treated an intrastent stenosis. MATERIALS AND METHODS: Observational, ambispective, crosssectional and comparative study consisting of the evaluation of patients with angina-compatible disease in the following 12 months to the treatment for intrastent stenosis. We reviewed the angiographies of the patients who entered the Cath Lab of the Hospital Central Militar for evaluation of intrastent restenosis due to previous balloon angioplasty or previous coronary intervention with implantation of a drug-eluting or bioabsorbable stent after angina. RESULTS: Three groups were treated with intrastent stenosis, the first using bioabsorbable stent, the second with drug-eluting stent and another group treated with a medicated balloon; in the control angiographies performed on patients with angina, a statistically significant difference was found in the therapy used for intrastent stenosis (15.7%, 65.1%, 70%, p < 0.001), with a higher success rate in bioabsorbable stent group in relation to the other two therapies. However, there was no difference in the treatment of intrastent stenosis with the use of drug-eluting stents vs. medicated balloon (65.1%, 70%, p < 0.75). ANTECEDENTES: la reestenosis del stent coronario es una hiperplasia neointimal que vuelve a obstruir el sitio tratado previamente. Su incidencia actual es de alrededor de 10% en pacientes tratados con stens medicados. El tratamiento es una reintervención con angioplastia con balón e implante de un segundo stent para restablecer el flujo sanguíneo adecuado. OBJETIVO: determinar si existe diferencia en relación con las distintas estrategias de tratamiento de la reestenosis intrastent, como: endoprótesis bioabsorbible, stent liberador de fármaco y balón medicado, valoradas por angiografía a los 12 meses de haber sido tratada una estenosis intrastent. MATERIALES Y MÉTODOS: estudio observacional, ambispectivo, transversal y comparativo consistente en la evaluación de pacientes con